Reve Image is a new online AI image generator that is going viral on social media. It's fast and incredibly easy to use.

On Wednesday, H.C. Wainwright reaffirmed a Buy rating and a price target of $54.00 on Biohaven Pharmaceutical (TADAWUL:2070) ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

HC Wainwright reissued their buy rating on shares of Biohaven (NYSE:BHVN – Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $54.00 price target on the stock.

In a report released yesterday, Leonid Timashev from RBC Capital maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price target of $61.00. The company’s shares closed ...

Bio­haven’s potas­si­um chan­nel drug has failed a late-stage study in bipo­lar ma­nia, ac­cord­ing to a state­ment in the com­pa­ny’s fourth-quar­ter earn­ings re­port.

Biohaven acquired BHV-7000 as part of a February 2022 buyout of Channel Biosciences. Image credit: Shutterstock / ma_Design. Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint ...

Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its protein degrader candidate that investors found underwhelming. Biohaven on ...

Today, a brief rundown of news involving Acelyrin and Neumora Therapeutics, as well as updates from Biohaven, Lexicon Pharmaceuticals and Pliant Therapeutics you may have missed. Shares of Lexicon ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...